SERP1 and angina pectoris: In the Phase 2 trial (NCT00243308), Serp-1 treatment was tested in a randomized, blinded, dose-escalating trial in patients with documented unstable coronary syndromes (patients with Non-ST elevation MI and unstable angina who required coronary angiography and had demonstrated indications for coronary stent implant).